Why Henry Schein (HSIC) Is Back In The Spotlight
Henry Schein (HSIC) is back in focus after reporting second quarter 2026 adjusted earnings and net sales that topped expectations, alongside higher full year guidance for both adjusted earnings and sales growth.
Henry Schein’s share price has gained 16.9% year to date and 16.0% over the past 90 days, while the 1 year total shareholder return of 29.4% and 3 year total shareholder return of 21.6% point to building momentum around the company’s recent earnings beat, raised guidance, and new supplier role with DermaSensor.
Scan for other healthcare stocks that may be setting up for similar earnings and guidance momentum using the hand picked list of solid balance sheet and fundamentals (52 results).
The strong year-to-date run in Henry Schein now puts the focus on valuation. After this move, does the current price still leave enough potential upside relative to the risks you are taking on the stock?
Most Popular Narrative: 7.9% Undervalued
Henry Schein's most followed valuation narrative puts fair value at $97.56 compared with the latest close at $89.81, which implies some remaining upside if those assumptions play out.
The company is experiencing strong growth in high-margin businesses such as Specialty Products, Technology, and private-label offerings, and expects over 50% of non-GAAP operating income to come from these segments, supporting structurally higher gross margins and likely driving earnings expansion. Investments in digital workflow, AI solutions, and integrated cloud-based practice management platforms are accelerating recurring SaaS revenues and client retention. This positions Henry Schein to benefit from the ongoing digital transformation of healthcare, which should support both revenue growth and improved margins.
Want to see what is built into that $97.56 figure? The narrative leans on a detailed path for revenue, margin mix and future earnings multiples. The key assumptions behind that path are where the real story sits.
Result: Fair Value of $97.56 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that narrative can quickly change if competitive pricing continues to pressure distribution margins or if execution on cost savings and technology investments at Henry Schein falls short.
Find out about the key risks to this Henry Schein narrative.
Next Steps
If the mixed signals on Henry Schein leave you unsure, move quickly from headline impressions to the underlying data and form your own view with the 2 key rewards and 1 important warning sign
Looking for more investment ideas beyond Henry Schein?
If Henry Schein has sharpened your interest in healthcare and quality fundamentals, you can use this momentum to broaden your watchlist with other high conviction opportunities.
- Target resilient balance sheets and steady fundamentals by scanning the list of solid balance sheet and fundamentals (52 results).
- Hunt for quality at attractive prices by reviewing the 47 high quality undervalued stocks.
- Spot strong businesses that the market may be overlooking with the 19 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com